Aims To investigate the clinicopathological and molecular characteristics of uterine tumours resembling ovarian sex cord tumours (UTROSCTs) and the value of molecular diversity in the clinical diagnosis and treatment.
Methods Five patients with UTROSCT were enrolled, and their clinical data, pathological morphologies, immunophenotypes and molecular features were analysed. Fluorescence in situ hybridisation for NCOA1, NCOA2, NCOA3, JAZF1 and PHF1 and next-generation sequencing for 27 homologous recombination/repair (HRR) pathway genes were performed on five and three UTROSCT specimens, respectively.
Results All five patients were treated for abnormal uterine bleeding and grossly presented with intrauterine polyps. Under a microscope, tumour cells grew diffusely and presented a cordlike arrangement and glandular duct-like structures, with nuclei ranging from round to oval, vesicular chromatin and visible nucleoli in some cases. The mitotic count was less than 3/10 high-power fields. Immunohistochemistry showed sex cord, epithelial cell and smooth muscle cell biomarkers and diffuse, strong staining for B cell lymphoma-2 (BCL-2). NCOA1 and NCOA3 rearrangements were identified in 80% (4/5) of the cases. JAZF1 and PHF1 rearrangements were not detected in any of five patients. HRR pathway gene mutations were detected in all three patients, including FANCE, ATR and ARID1A mutations in one case each.
Conclusion UTROSCT is a rare mesenchymal tumour, and biopsy specimens are easily misdiagnosed. UTROSCT diagnosis requires the combined use of biomarkers and molecular detection. BCL-2 has potential diagnostic value as a marker. UTROSCT can have mutations related to the HRR pathway, suggesting that this tumour type may be sensitive to platinum/poly (ADP-ribose) polymerase inhibitors.
- uterine cervical neoplasms
- ovarian neoplasms
Data availability statement
All data relevant to the study are included in the article
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Uterine tumour resembling ovarian sex cord tumour (UTROSCT) is a rare type of tumour with unclear origins and is defined histologically by sex cord–like growth patterns, such as sheets, nests, trabeculae, cords or tubules, with/without Sertoli-like or Leydig-like components, and immunohistochemically by variable sex cord markers in addition to epithelial, myogenic and sex hormone markers.1–4 UTROSCTs are most common in perimenopausal and postmenopausal women, with an average age of approximately 50 years, and the main clinical presentation is abnormal uterine bleeding and/or abdominal pain.1 5 Due to the low incidence, our understanding of UTROSCT is very limited, and it is prone to misdiagnosis.
Homologous recombination/repair (HRR) is an important repair method for DNA double-strand damage to maintain the integrity of the genome and ensure the transmission of genetic information in high fidelity. HRR is a complex signalling pathway, and BRCA1 and BRCA2 are the key proteins. Mutations in HRR-related genes can cause homologous recombination deficiency (HRD) and lead to genomic instability, and tumour cells often use HRR to prevent cell apoptosis.6 However, when tumour cells develop HRD and poly (ADP-ribose) polymerase (PARP) is inhibited, a ‘synthetic lethal’ effect will occur, and tumours with HRD are more sensitive to platinum/PARP inhibitors.6 7
UTROSCTs appear to have low malignant potential. However, cases with recurrence and even metastasis to remote sites have been reported.7–9 Therefore, for patients with UTROSCT who cannot tolerate surgery or experience metastasis or recurrence, other potential treatments must be identified. This study attempted to further analyse the nature of this tumour by studying its clinicopathological characteristics and gene variations to provide a basis for clinical diagnosis and prognostic prediction.
Materials and methods
Five patients aged 39–65 years who were diagnosed with UTROSCT between 2014 and 2020 were enrolled in the study. These patients sought treatment due to abnormal uterine bleeding, and pathological sections were reviewed by two senior pathologists.
All specimens were fixed in 3.7% neutral formalin and embedded in paraffin, and 20 consecutive sections were generated for H&E and immunohistochemical staining. Immunohistochemistry was performed using a BenchMark XT automated slide stainer (Roche, the USA). Four primary antibodies came in ready-to-use working solutions: cluster of differentiation 10 (CD10, rabbit monoclonal antibodies (mAb), SP67, Roche), oestrogen receptor (ER, rabbit mAb, SP1, Roche), progesterone receptor (PR, rabbit mAb, 1E2, Roche) and smooth muscle actin (SMA, mouse mAb, 1A4, MXB Biotechnologies, Fuzhou, China). Other primary antibodies, against pan-cytokeratin (CKpan, mouse mAb, AE1/mA3), epithelial membrane antigen (EMA, mouse mAb, GP1.4), B cell lymphoma-2 (BCL-2, mouse mAb, bcl/100/D5), α-inhibin (mouse mAb, AMY82), calretinin (rabbit polyclonal antibody), steroidogenic factor-1 (SF-1, mouse mAb, OTI1H2), Wilms’ tumour 1 (WT-1, mouse mAb, 6F-H12), cluster of differentiation 99 (CD99) (rabbit mAb, EP8), desmin (rabbit mAb, EP15), h-caldesmon (rabbit mAb, EP19) and antigen Ki-67 (mouse mAb, UMAB107), were purchased from ZSGB Biotech, Beijing, China. The secondary antibody was the Roche universal horseradish peroxidase–labelled antibody mixture (goat anti-mouse IgG, goat anti-mouse IgM and goat anti-rabbit). Primary antibodies were conjugated using a cocktail of enzyme-labelled secondary antibodies. Diaminobenzidine was used for colour development. Haematoxylin was used for nuclear counterstaining.
Fluorescence in situ hybridisation (FISH)
Five tumour tissue samples were subjected to FISH to identify molecular rearrangements of NCOA1, NCOA2, NCOA3, JAZF1 and PHF1 (all from Guangzhou Anbiping Pharmaceutical Technology, China). FISH was performed as described previously.5 Briefly, the unstained slides were deparaffinised, pretreated and hybridised to denatured probes. Then, after more than 6 hours of incubation at 37°C, the slides were washed and counterstained with diamidine phenyl indole (DAPI), mounted and analysed using a Zeiss fluorescence microscope (Olympus BX51, Tokyo, Japan).
Next-generation sequencing (NGS)
Tumour tissue samples and the corresponding paracancerous tissues collected over the last 3 years from three patients with UTROSCT were subjected to multigene sequencing of 27 HRR pathway-related genes (sequencing was completed by Shanghai Zhengu Biotechnology, China): BRCA1, BRCA2, PIK3CA, KRAS, NRAS, BRAF, ATM, ATR, BARD1, BRIP1, CHEK2, CTNNB1, FANCA, FANCC, FANCD2, FANCE, FANCF, PTEN, MRE11A, NBN, PALB2, PPP2R1A, RAD50, RAD51, RAD51C, RAD51D and ARID1A. The average sequencing depth was 3000X, and the on-target rates were greater than 95%. The obtained mutations were filtered to retain only non-synonymous mutations, stop-gain mutations, frameshift mutations and splicing mutations. The common mutations were filtered out according to the frequency in the population. Finally, the mutations that impaired protein function, based on the results of the prediction software, were retained.
As shown in table 1, the ages of the patients ranged from 39 to 65 years, with a median age of 53 years. The clinical manifestations included two cases of postmenopausal vaginal bleeding (cases 2 and 3) and other three cases of increased menstrual bleeding and prolonged periods. B-mode ultrasound suggested hypoechoic intrauterine nodules. One patient underwent hysteroscopic electrical resection (case 4), and other four patients underwent hysterectomy and bilateral adnexectomy. In general, two patients had intramural nodules protruding into the uterine cavity; two patients had intrauterine polypoid masses with a greyish-brown section, the texture of which was soft to slightly tough, and some of the polyps were lobulated with visible borders with the myometrium; one patient had a fragmented cordlike tissue (case 4), and the tumour size was 1.5–5 cm in diameter.
Under low magnification, tumor cells were arranged in a nested, trabecular, cord, reticular (figure 1A), glandular (figure 1B), small tubular and Call-Exner body-like follicular appearance (figure 1C), consisting of epithelial-looking cells and spindle-shaped cells, with scant interstitial hyaline degeneration. Under high magnification, the nuclei were oval, overlapping and without nuclear grooves, and the nucleoli were not obvious in three cases and were visible in two cases (figure 1D). The mitotic count was 0–2/10 high-power fields. Borders of the myometrium were unclear in all five patients (figure 1), which were observed even in hysteroscopic resection specimens. One patient showed obvious tonguelike infiltration (case 1) without vascular involvement, and haemorrhage and necrosis were noted on the surface of the tumour in one case (case 3). Two patients had endometrial polyps (cases 4 and 5), and two patients had uterine leiomyomas.
As shown in table 2, more than two sex cord markers were expressed in all five patients. The positive expression rates of α-inhibin, WT-1, SF-1 (figure 2A), calretinin (figure 2B) and CD99 were 1/5, 2/5, 3/5, 4/5 and 4/5, respectively. All patients expressed one or more smooth muscle markers, and the positive expression rates of desmin, SMA, and h-caldesmon (figure 2C) were 3/5, 4/5 and 5/5, respectively. CKpan (figure 2D), BCL-2 (figure 2E), ER and PR expressions were observed and EMA was negative in all five patients. The CD10-positive rate was 4/5, and the positive rate of Ki-67 was 5%–15% in all five patients (figure 2F).
NCOA1 (figure 3A) gene breaks were detected in cases 1, 2 and 3. NCOA3 gene breaks was detected in case 4. Case 5 did not have any of these gene breaks. NCOA2, JAZF1 (figure 3B) and PHF1 gene breaks were not detected in any of the five patients.
Somatic pathological mutations were detected in three patients. FANCE gene Exon 1 pW19X stop-gain mutation (G–A) was detected in case 4, resulting in the acquisition of a stop codon. The ATR gene Exon 9 pI710Yfs5 frameshift mutation (AT–A) was detected in case 3. The ARID1A gene Exon 1 pP21del non-frameshift mutation (CCCG–C) was detected in case 2. No suspected pathogenic germline mutations in the HRR-related pathway genes were found in the three patients.
Treatment and follow-up
Four patients underwent hysterectomy and bilateral adnexectomy, one patient underwent hysteroscopic resection and all five patients were followed up. None of the patients received further postoperative treatment. The follow-up time was 4–72 months (average 20 months), and no recurrence or metastasis was noted.
Uterine tumours with sex cord–like elements were first proposed by Clement et al in 1976.10 Based on their biological behaviour, this type of tumour was classified into two groups. Group I is endometrial stromal tumours with foci of sex cord–like elements (sex cord elements <50%), which usually show recurrence and metastasis. Group II is composed predominantly or exclusively of sex cord–like elements (>50%). They are mostly benign and generally do not recur or metastasise. In the 2003 version of the WHO classification, group II was included in the ‘other’ types of mesenchymal tumours, and the diagnosis was uterine sex cord–like tumour. In the 2014 version of the WHO classification, group I was included in the low-grade endometrial stromal tumours, while group II tumours were individually categorised as UTROSCT. This emphasised that only when tumours lack classic endometrial stromal tumour elements can this diagnosis be made.11
Compared with low-grade endometrial stromal tumours with sex cord–like differentiation, UTROSCT lacks the JAZF1–SUZ12 (two zinc finger protein genes) fusion gene or the PHF1 rearrangement.12 Both JAZF1 and PHF1 were absent in all five of our patients, which is useful for distinguishing UTROSCT from low-grade endometrial stromal tumours with sex cord–like differentiation. In addition, UTROSCT lacks the FOXL2 mutation in adult granulosa cell tumours of the ovary and has the dicer 1, ribonuclease III mutations in Sertoli-Leydig cell tumours, although UTROSCT can express FOXL2 as detected by immunohistochemistry.13
UTROSCT may represent an independent tumour unrelated to endometrial stromal tumours and ovarian sex cord–stromal tumours. Dickson et al 14 recently reported that UTROSCT includes NCOA2 or NCOA3 gene fusions, suggesting that UTROSCT is an independent tumour. Goebel et al 5 also reported that UTROSCTs show NCOA2–3 gene fusions, and novel rearrangements involving NCOA1 were identified. In all, 81.8% (18/22) of cases showed NCOA1–3 fusions, emphasising that UTROSCT is a distinct entity and that the detection of these gene fusions is useful in differentiating this tumour from other entities. In our study, NCOA1 and NCOA3 were identified in 80% (4/5) of our patients, which provides strong support for the diagnosis of UTROSCT.
The immunohistochemical features of UTROSCT are the multiple phenotypes of epithelial cells, smooth muscle cells, sex cord markers and hormone receptors.1 Among the five cases reported here, at least two of the sex cord markers α-inhibin, calretinin, SF-1, CD99 and WT-1 were positive. Among them, α-inhibin and SF-1 are currently the most specific markers for the diagnosis of ovarian sex cord–stromal tumours. Stewart et al 15 compared UTROSCT with other uterine tumours with sex cord differentiation and found that the sensitivity of calretinin in the diagnosis of UTROSCT was 100%, the specificity was 80% and the sensitivity and specificity of SF-1 were 50% and 100%, respectively. In our cases, three were positive for SF-1, which was consistent with the above reports, suggesting that sex cord differentiation is a concomitant feature in uterine tumours but is intrinsic in UTROSCT. Cytokeratin (CK) was positive, and EMA was negative in all five cases, consistent with the traits of ovarian sex cord–stromal tumours.16 The positive expression of CK can easily lead us to misdiagnose it as an epithelial malignant tumour, especially in biopsy specimens. In these cases, EMA should be included for diagnosis.
We inadvertently found strong, diffuse BCL-2 positivity in one patient with UTROSCT, so we retrospectively performed immunohistochemistry for BCL-2 in the other four cases and surprisingly found that all tumours diffusely and strongly expressed BCL-2. In 2003, Wang et al 17 also reported diffusely and strongly expressed BCL-2 in one patient with UTROSCT. This patient had a translocation on chromosomes t(4; 18) (q21.1; q21.3) and t(x; 6) (p22.3; q23.1), which the authors suggest is associated with the inclusion of important oncogenes such as BCL-2 and MALT1 on chromosome 18. BCL-2 antagonises cell apoptosis,18 but the mechanism is not clear. BCL-2 overexpression may have potential value in the diagnosis of UTROSCT; however, more cases need to be investigated.
The differential diagnosis included the following
Epithelioid leiomyoma: Epithelioid leiomyoma has similarities to UTROSCT, and both show clear boundaries, soft textures, yellow or grey cross sections, round or polygonal tumour cells and cells arranged in tufts and cords under a microscope. However, epithelioid leiomyomas are commonly associated with the transition of spindle-shaped smooth muscle cells, and they lack the UTROSCT-like sex cord–like phenotype based on immunohistochemistry.
Endometrial stromal sarcomas or endometrial stromal nodules with sex cord differentiation: Histologically, a typical area of an endometrial stromal tumour can always be found, such as characteristic small arteries, proliferation of endometrial stromal cells and diffusely positive CD10, while its sex cord–differentiated areas are indistinguishable from UTROSCT. When the two are difficult to distinguish, molecular detection can be performed. Endometrial stromal tumours show specific t(7;17) (p15;q21) translocations, resulting in JAZF1–SUZ12 gene fusion.
Endometrial cancer (epithelial malignant tumour): In biopsy specimens, the epithelioid-like structure of UTROSCT, broad-spectrum CK positivity and clinical history of abnormal vaginal bleeding can easily lead us to misdiagnose it as an epithelial malignant tumour, but misdiagnosis can be avoided with the careful observation of the mitotic figures and nuclear heterogeneity.
Among these five patients with UTROSCT, two fertile patients also had endometrial polyps, including one case of multiple polyps, and two menopausal patients also had multiple uterine leiomyomas. Is the occurrence of UTROSCT related to a high oestrogen level? Some patients with UTROSCT have had breast cancer and tamoxifen treatment histories, so more clinical data need to be accumulated.19 20
For patients with UTROSCT, surgical intervention is an effective treatment, and the prognosis of most patients is good. However, in a study with long-term follow-up (average 39 months) published in 2017, 23.5% (8/34) of the patients had recurrence and metastasis.21 Therefore, UTROSCT has obvious malignant potential, with no reliable prognostic factor in histology. The adjuvant treatment approaches for these eight patients with recurrence were different, and eventually, three patients died of this tumour. It has recently been found that UTROSCT has the recurrent fusion of NCOA2 or NCOA3, its partner genes are ESR1 and GREB1 14 and recurrence has been associated with GREB1,5 which underscores the possible value of molecular detection in predicting prognosis. Therefore, for patients with UTROSCT who cannot tolerate surgery or experience metastasis or recurrence, choosing an effective treatment is a new challenge. However, there is very little evidence to aid decision making.
HRR is an important repair method for DNA double-strand damage, and defects in this pathway usually lead to tumorigenesis.6 HRD has been observed in some patients with ovarian cancer or breast cancer,22 especially in patients with high-grade ovarian serous carcinoma,23 who are sensitive to platinum-containing drugs and PARP inhibitors.6 24 HRR involves multiple steps; in addition to BRCA1/2, mutations in other HRR-related genes can also cause HRD and lead to genome instability.25 Pellegrino et al 26 performed germline and systemic mutation sequencing of 13 HRR-related genes in 390 cases of ovarian cancer and found that patients with germline or systemic HRR-related gene mutations were highly correlated with platinum-based treatment sensitivity and good prognosis. For this reason, some researchers put forward the concept of ‘BRCAness’, which describes HRD that does not have BRCA mutations but has a phenotype similar to BRCA mutation tumours.27 Therefore, the detection of HRD needs to integrate the detection of BRCA1/2 and other HRR-related genes to more effectively screen the population for platinum/PARP inhibitors.
With the key advances in NGS technology, NGS has expanded our understanding of HRD and related gene instability in more tumour types. To understand whether these drugs can benefit patients with UTROSCT, we detected 27 HRR pathway-related genes by NGS, and the results showed that suspected pathogenic somatic mutations were detected in all three of patients, including FANCE, ATR and ARID1A. ATR kinase is a RAD3-related protein that can directly phosphorylate the protein encoded by the tumour suppressor gene p53 and cell cycle regulatory proteins; ATR and its associated signalling pathways are critical to genome stability and the occurrence and development of various tumours.28 FANCE belongs to the Fanconi anaemia complementation group and is mainly responsible for cytogenetic stability and DNA repair.29 Moreover, FANCE is associated with sensitivity to platinum drugs in ovarian carcinoma.30 To our knowledge, our discovery fills the gap in research on the HRR pathway in UTROSCT, and the results suggest that patients with UTROSCT may also be sensitive to platinum/PARP inhibitors.
Take home messages
Tumours resembling ovarian sex cord tumour (UTROSCT) is a rare type of tumour that requires the combined use of biomarkers and molecular detection for diagnosis.
Immunohistochemistry showed diffuse and strong expression of B cell lypmphoma-2 (BCL-2) in all patients. BCL-2 overexpression may have potential value in the diagnosis of UTROSCT.
UTROSCT can have mutations related to the homologous recombination/repair pathway, suggesting the presence of repair gene instability in this tumour type, which is in line with its borderline or malignant behaviour; thus, this tumour may be sensitive to platinum/poly (ADP-ribose) polymerase (PARP) inhibitors.
Data availability statement
All data relevant to the study are included in the article
Patient consent for publication
Approval was obtained from the ethics committee of the First Affiliated Hospital of USTC (No: 2021-BLK-04).
Handling editor Mona El-Bahrawy.
Contributors SY: Manuscript writing/editing and data collection. JW: Technical assistance and data collection. LY: Technical assistance and manuscript editing. JH: Study concept and design and project development.
Funding This study was financed by the National Natural Science Foundation of China (81872055).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.